How to Bring Biomarker Testing In-House for Cancer Targeted Treatment Selection

 

Personalized cancer treatment via targeted therapies is two-to-three times more effective than standard chemotherapy for patients with advanced or metastatic cancer. But for patients to benefit, they must have access to robust biomarker testing capabilities, a challenge in many community cancer settings. Yet this testing is time-consuming and costly to outsource.

The solution? Imagia Canexia Health can help your lab deploy cancer genomics assays at a fraction of the cost of outsourcing multigene panels to a centralized lab, and without the need to invest in a costly bioinformatics infrastructure.

Our Clinical Services team supports labs with bringing precision oncology programs in-house, including the implementation and maintenance of clinical next-generation sequencing-based profiling.

Watch our video to learn how we can help you deliver on your mandate for providing best-in-class cancer care.

Related posts

Digital Technology Supercluster Announces Investment to Increase the Effectiveness of Precision Oncology

Digital Technology Supercluster Announces Investment to Increase the Effectiveness of Precision Oncology

Harnessing artificial intelligence to take the guesswork out of diagnosing cancer recurrence for millions of cancer survivors

Read more
How to Bring Biomarker Testing In-House for Cancer Targeted Treatment Selection

How to Bring Biomarker Testing In-House for Cancer Targeted Treatment Selection

Personalized cancer treatment via targeted therapies is two-to-three times more effective than standard chemotherapy for patients with advan

...
Read more
Imagia Cybernetics & Canexia Health Merge to Supercharge Precision Oncology Accessibility

Imagia Cybernetics & Canexia Health Merge to Supercharge Precision Oncology Accessibility

Imagia Cybernetics, an AI-healthcare company that accelerates oncology solutions generated from real world data, today announced its merger

...
Read more